Revium Rx (RVRC)

Market Cap	31.58M
Revenue (ttm)	n/a
Net Income (ttm)	-2.07M
Shares Out	60.73M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	299
Average Volume	1
Open	0.5200
Previous Close	0.5200
Day's Range	0.5200 - 0.5200
52-Week Range	0.3000 - 0.5200
Beta	-1.19
RSI	100.00
Earnings Date	n/a

About Revium Rx

Revium Rx, a pre-clinical stage biopharmaceutical company, develops nano-liposomal particles (NLP) based pharmaceutical candidates. It develops nanoparticles-based formulation of a potent antibiotic; novel adjuvant for cancer therapies: and novel immunization based on liposomal protein-loaded technology. The company was formerly known as Revium Recovery Inc. and changed its name to Revium Rx. in December 2024. Revium Rx was incorporated in 1997 and is based in Herzliya, Israel.

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1997
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: RVRC